In recent years, the increasing amount of patient data available in datasets (e.g., The Cancer Genome Atlas (TCGA), The Human Protein Atlas, Oncomine etc.), provide strong support for CCT as a driver of cancer and potentially an oncogene (Klimczak et al., 2019; Dong et al., 2020; Liu et al., 2020). The gene discussed is FLVCR2; the disease is cancer.